Meridian SensiFAST New obesity paper Flyer

Summary As demonstrated here, SensiFAST ™ cDNA Synthesis Kit can be used to generate cDNA directly from crude lysate, without the need to purify the RNA first. This method can save considerable time, increase assay throughput, avoid potential contamination, eliminate the use of organic solvents, and dramatically reduce costs. In addition, SensiFAST ™ Lo-ROX Mix can reproducibly amplify gene targets from crudely produced cDNA with high sensitivity in singleplex or multiplex assays. These reagents are ideal for studies requiring amplification from low copy number targets or for deciphering subtle changes in gene expression levels. 1. sheets/detail/obesity-and-overweight 2. Hruby, A., & Hu, F. B. (2015). The Epidemiology of Obesity: A Big Picture. PharmacoEconomics , 33(7), 673–689. 3. Thaker V. V. (2017). Genetic and epigenetic causes of obesity. Adolescent medicine: state of the art reviews , 28(2), 379–405. 4. Tikellis, C., Pickering, R.J., Tsorotes, D., Thomas M. (2012). Activation of the Renin- Angiotensin System Mediates the Effects of Dietary Salt Intake on Atherogenesis in the Apolipoprotein E Knockout Mouse. Hypertension 60(1), 98-105. 5. Karen Liao, Daniel Sikkema, Catherine Wang, Thomas N. Lee. (2013). Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2),JJ. Immunological Methods, 389(1–2), 52-60. 6. Kantharidis P., Hagiwara S., Brennan E., McClelland A. D. (2015). Study of microRNA in diabetic nephropathy: Isolation, quantification and biological function. Nephrology. 20(3), 132-139 7. Pickering, R. J., Tikellis, C., Rosado, C. J., Tsorotes, D., Dimitropoulos, A., Smith, M., Huet, O., Seeber, R. M., Abhayawardana, R., Johnstone, E. K., Golledge, J., Wang, Y., Jandeleit-Dahm, K. A., Cooper, M. E., Pfleger, K. D., & Thomas, M. C. (2019). Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. The Journal of clinical investigation, 129(1), 406–421.

(RAGE) and Human Caco2 cells (ACE2) using previously established methods 6 . Specifically, cells were lysed using 50 μL and 200 μL respectively of pre-prepared lysis buffer 6 and 2 μL of the diluted lysate mixture was added to 4 μL 5 x buffer, 0.2 μL RNase inhibitor, 1 μL MMLV-RT and made up to 20 μL with water. The mix was then incubated at 25 °C for 10 minutes, 42 °C for 60 minutes, 80 °C for 5 minutes and then stored at -20 °C. To examine the basal expression levels of RAGE in Human Lung cells and ACE2 in Human Caco-2 cells, 1 μL of the cDNA mixture prepared as per above, was added to 1.5 μL of primer mix and 5 μL 2 x SensiFAST ™ Probe Lo-ROX Mix and made up to 10 μL with water. PCR was performed using 6 μL of this mix with the following cycling conditions: 95 °C for 20 sec, then 40 cycles of 95°C at 1 sec followed by 60 °C for 20 sec. If the Ct was later than 33 cycles, then 10 μL reaction volumes were used instead. Both RAGE and ACE2 expression levels were consistently detected at similar levels over repeat experiments, demonstrating that this protocol, using SensiFAST ™ Probe Lo-ROX Mix for PCR analysis, circumvents the need to purify RNA, allowing cDNA synthesis directly from the cell lysate, saving considerable time, avoiding contamination, eliminating the use of organic solvents, increasing throughput and dramatically reducing costs. Multiplex Gene Expression Analysis Direct from Crude Lysate using SensiFAST™ cDNA Synthesis Kit and SensiFAST™ Probe Lo-ROX Several studies have shown that the failure to resolve inflammation may contribute to the progression of many chronic inflammatory disorders. Reducing inflammation through a targeted approach has been suggested as a novel treatment for chronic inflammatory diseases such as diabetes. Lipoxins, a class of endogenously generated mediators, promote the resolution of inflammation and Lipoxin A4 (LXA4) specifically has strong neuroprotective effects in diabetes by reducing the inflammatory reaction in cerebral ischemia/reperfusion injury. It is thought that LXA4 might reduce the levels of

monocyte chemoattractant protein-1 (MCP-1) which is often associated with diabetic microvascular or macrovascular complications. In this study, the LXA4 downregulation of MCP-1 expression was examined in mice kidney cells (Figure 2). Specifically, the difference in MCP-1 expression levels after treatment with LX4 or a mimetic (LXM1 or LXM2) was measured using SensiFAST ™ Probe Lo-ROX. In this experiment, cDNA from purified RNA was obtained from mouse kidney samples using SensiFAST cDNA Synthesis Kit, where the mice were either in a control or diabetic group, and treated with LXA4, LXM1, or LXM2. Crude lysate was prepared according to the protocol in the SensiFAST ™ cDNA Synthesis Kit except the 42°C step was extended to 60 min in the cDNA synthesis reaction in order to obtain a similar yield of cDNA from lysate as from purified RNA. The relative expression of MCP-1 was measured using SensiFAST Probe Lo-ROX in a multiplex reaction with MCP-1 and 18s as a housekeeping gene. The results show that LXA4 does appear to have a protective effect, reducing the levels of MCP-1, when compared to mimetics.

Effect of Lipoxin A4 (LXA4) on MCP-1 Expression in Mice Kidney Cells


Vehicle LXA4 LXM1 LXM2











*** ***




Treatment groups

Figure 2. qPCR using SensiFAST™ Probe Lo-ROX to examine the difference in MCP-1 expression levels after treatment with LXA4 or mimetics LXM1 or LXM2. A highly sensitive qPCR mix was required to discriminate the different levels in expression between treatment groups.

Ordering information: USA 5171 Wilfong Road

Email: Orders:

Memphis, Tennessee 38134 Phone: +1 901-382-8716 Fax: +1 901-333-8223

Connect with us:

ISO 13485 Certified


Powered by